glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-14. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Beta hairpin Extremely common. Two antiparallel beta strands connected by a tight turn of a few amino acids between them. Greek key Four beta strands, three connected by hairpins, the fourth folded over the top. Omega loop A loop in which the residues that make up the beginning and end of the loop are very close together. Helix-loop-helix Consists of alpha helices bound by a looping stretch of amino acids. This motif is seen in transcription factors. Zinc finger Two beta strands with an alpha helix end folded over to bind a zinc ion. Important in DNA binding proteins. Helix-turn-helix Two α helices joined by a short strand of amino acids and found in many proteins that regulate gene expression. Nest Extremely common. Three consecutive amino acid residues form an anion-binding concavity. Niche Extremely common. Three or four consecutive amino acid residues form a cation-binding feature.
Allysine is involved in the production of elastin and collagen. Increased allysine concentration in tissues has been correlated to the presence of fibrosis. Allysine residues react with sodium 2-naphthol-6-sulfonate to produce a fluorescent bis-naphtol-allysine product. In another assay, allysine-containing proteins are reduced with sodium borohydride to give a peptide containing the 6-hydroxynorleucine (6-hydroxy-2-aminocaproic acid) residue, which (unlike allysine) is stable to proteolysis.
== Pharmacology == The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection until they are broken down by proteases. The two collagenases act synergistically by cleaving tropocollagen (the 'collagen molecule') at different points. AUX-I attacks the C- and N-termini, AUX-II cleaves amino acid bonds within the molecule. Small collagen fragments are broken down by both enzymes.
The first widely accepted set of classification criteria for research purposes was elaborated in 1990 by the Multicenter Criteria Committee of the American College of Rheumatology. These criteria, which are known informally as "the ACR 1990", defined fibromyalgia according to the presence of the following criteria:
Sources: en.wikipedia.org
Meyer (1940), composer, author, philosopher known for his contributions to the aesthetic theory of music Orrin Keepnews (1943), jazz record producer and winner of the 1988 Grammy Award for Best Album Notes and Best Historical Album Mort Lindsey (1944), musical director for Judy Garland and Merv Griffin Dick Hyman (1948), musical director for Arthur Godfrey; composer or arranger for Hannah and Her Sisters and The Purple Rose of Cairo; Emmy Award winner Philip Springer (1950), composer known for writing the song "Santa Baby" Randy Starr (1951), dentist and composer for Elvis Presley Eric Salzman (1954), composer, producer, critic; founder of the American Music Theater Festival and composer-in-residence of the Center for Contemporary Opera Malcolm Frager (1955), piano virtuoso Mike Berniker (1957), musical producer and winner of nine Grammy Awards Billy Goldenberg (1957), composer and winner of four Emmy Awards John Corigliano (1959), winner of the Pulitzer Prize for Music and Academy Award for Best Original Score Edward Kleban (1959), lyricist for A Chorus Line David Bromberg* (1960s), Grammy Award-nominated musician Art Rosenbaum (1960), Grammy Award-winning art professor and musician at Georgia State University Charles Wuorinen (1961), serialist composer and winner of the Pulitzer Prize for Music for Time's Encomium Charlie Morrow (1962), sound artist and musician Joel Krosnick (1963), chamber musician and member of the Juilliard String Quartet David Rubinson (1963), record and music producer of Apocalypse Now, founder of San Francisco Records and The Automatt recording studio Art Garfunkel (1965), singer of Simon and Garfunkel, famous for the song "The Sound of Silence" Daniel Waitzman (1965), flutist and composer Kenneth Ascher (1966), Academy Award-nominated jazz pianist; writer of "Rainbow Connection" from The Muppet Movie David Schiff (1967), composer Tom Werman (1967), former record producer for Epic Records Billy Cross (1968), guitarist, singer, and producer who lives in Denmark Jon Bauman (1969), "Bowzer" of Sha Na Na James "Plunky" Branch (1969), jazz musician Cameron Brown (1969), jazz bassist Emanuel Ax (1970), concert pianist Marc Copland (1970), jazz pianist and composer Scott Simon (1970), member of Sha Na Na Frederick "Dennis" Greene (1971), member of Sha Na Na; professor of law at the University of Dayton Armen Donelian (1972), jazz pianist Jocko Marcellino (1972), member of Sha Na Na Phil Schaap (1973), Charlie Parker authority and multiple Grammy Award winner for engineering, production, and album notes Eugene Drucker (1973), Grammy Award-winning violinist, member of the Emerson String Quartet Sam Morrison (1973), saxophonist Michael Jeffrey Shapiro (1973), composer and conductor Richard Einhorn (1975), composer, Voices of Light Phil Kline (1975), composer Paul Phillips (1978), conductor, composer, and music scholar at Brown University Erik Friedlander (1982), cellist, son of American photographer Lee Friedlander Robbie Fulks* (1984), Grammy Award-nominated American alternative country singer-songwriter Dave Nachmanoff (1986), award-winning folk singer and sideman to Al Stewart John Bohlinger (1988), musician and music director on NBC program Nashville Star Laura Cantrell (1989), country musician Peter J. Nash (1989), member of 3rd Bass Mac McCaughan (1990), member of indie rockband Superchunk and founder of Merge Records Richard Carrick (1993), pianist, composer, professor at Berklee College of Music Gil Shaham (1993), violinist Jefferson Friedman (1996), composer Tom Kitt (1996), composer, co-winner of the 2010 Pulitzer Prize for Drama and the Tony Award for Best Original Score for his score of the musical Next to Normal R. Luke DuBois (1997), composer and artist Lauryn Hill* (1997), Grammy Award-winning R&B singer and songwriter, and member of The Fugees Sean Lennon* (1997), singer and songwriter, and son of John Lennon and Yoko Ono Orli Shaham (1997), pianist Yelena Dudochkin (1998), Ukrainian-American soprano Scott Hoffman (1999), known by the stage name Babydaddy, member of the rock band Scissor Sisters The Two Man Gentlemen Band, modern musical duo that consists of Fuller Condon (2000) and Andy Bean (2001) Mason Bates (2000), Grammy Award-winning composer Tom Frank (2000), journalist, former member of indie-rock band Jonathan Fire*Eater Hikaru Utada* (2000), Japanese pop star Alicia Keys* (2001), Grammy Award-winning R&B singer and songwriter Brian Weitz (2001), founding member of experimental band Animal Collective Emily and Julia Bruskin (2002), members of the Claremont Trio Ken-David Masur (2002), musical director of the Milwaukee Symphony Orchestra, son of conductor Kurt Masur Ariana Ghez (2003), oboist Nico Muhly (2003), contemporary classical music composer Anna Bulbrook (2004), violinist formerly member of indie band The Airborne Toxic Event Alisa Weilerstein (2004), cellist and 2011 MacArthur Fellow Tristan Perich (2004), contemporary composer and sound artist Peter Cincotti (2005), pianist Ellen Reid (2005), composer and recipient of the 2019 Pulitzer Prize for Music Patrick Higgins (2006), composer, musician, producer Michael Barimo (2006), pop singer and whistler Rostam Batmanglij (2006), member of alt-rock band Vampire Weekend Ezra Koenig (2006), member of alt-rock band Vampire Weekend Chris Tomson (2006), member of alt-rock band Vampire Weekend Chris Baio (2007), member of alt-rock band Vampire Weekend Call Me Ace or Anthony Patterson (2011), rapper Adam Met (2013), member of pop band AJR Danny Mercer (2013), singer, songwriter and producer Nathan Chan (2014), cellist Conrad Tao (2015), composer, pianist, violinist Jack Met* (2019), member of pop band AJR Maude Latour (2022), singer-songwriter Annie Moon (2026), member of a co-ed K-Pop Group ALLDAY PROJECT
== United Kingdom == The Public Health Laboratory Service (PHLS) was established as part of the National Health Service in 1946. An Emergency Public Health Laboratory Service was established in 1940 as a response to the threat of bacteriological warfare. There was originally a central laboratory at Colindale and a network of regional and local laboratories. By 1955 there were about 1000 staff. These laboratories were primarily preventive with an epidemiological focus. They were, however, in some places located with hospital laboratories which had a diagnostic focus. The PHLS was replaced by the Health Protection Agency in 2003; the HPA was disbanded and in its stead was constituted Public Health England, which later became the UK Health Security Agency in 2021.
=== Reduction === Metal carbonyls react with reducing agents such as metallic sodium or sodium amalgam to give carbonylmetalate (or carbonylate) anions. Polynuclear or electron-imprecise clusters add the reductant to give mononuclear anions:
Pellagra is a disease caused by a lack of the vitamin niacin (vitamin B3). Symptoms include inflamed skin, diarrhea, dementia, and sores in the mouth. Areas of the skin exposed to friction and radiation are typically affected first. Over time, affected skin may become darker, stiffen, peel, or bleed. The two main types of pellagra are primary and secondary. Primary pellagra is due to a diet that does not contain enough niacin and tryptophan. Secondary pellagra is due to a poor ability to use the niacin within the diet. This can occur as a result of alcoholism, long-term diarrhea, carcinoid syndrome, Hartnup disease, and a number of medications such as isoniazid. Diagnosis is typically based on symptoms and may be assisted by urine testing. Treatment is with either nicotinic acid or nicotinamide supplementation. Improvements typically begin within a few days. General improvements in diet are also frequently recommended. Decreasing sun exposure via sunscreen and proper clothing is important while the skin heals. Without treatment, death may occur. The disease occurs most commonly in the developing world, often as a disease of poverty associated with malnutrition, specifically sub-Saharan Africa.
=== 1970s === 1975: Chien-Shiung Wu, born in China but having become an American citizen in 1954, became the first female president of the American Physical Society. 1976: Margaret Burbidge, born in England, was named as the first female president of the American Astronomical Society. 1977: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones"; she shared it with Roger Guillemin and Andrew V. Schally "for their discoveries concerning the peptide hormone production of the brain." 1978: Anna Jane Harrison became the first female president of the American Chemical Society. 1978: Mildred Cohn served as the first female president of the American Society for Biochemistry and Molecular Biology, then called the American Society of Biological Chemists.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.